Evidence map›Paper›PMID 40246748›Full record

ArticleDiscover nano2025

Doxorubicin delivery of green-synthesized gold nanoparticles to MDA-MB-231 cells and collagen type II identification from yellow nose skate cartilage.

Eun-Young Ahn, Youmie Park

Abstract read
In one paragraph

Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eun-Young AhnCollege of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Inje-ro, Gimhae, Gyeongnam, 50834, Republic of Korea.
Youmie ParkCollege of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Inje-ro, Gimhae, Gyeongnam, 50834, Republic of Korea. youmiep@inje.ac.kr.

Funding

National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) RS-2024-00452407
6 · The paper itself

Abstract

Upcycling and green synthesis strategies have been applied for the synthesis of gold nanoparticles (AuNPs) using yellow nose skate (Dipturus chilensis) cartilage extract as a reducing and stabilizing agent (skAu). Doxorubin (DOX) was loaded onto the skAu, and the average size of the DOX-loaded AuNPs (c-skAuD) was measured to be 14.6 ± 0.5 nm by high-resolution transmission electron microscopy. Reaction parameters such as reaction time and DOX concentration were optimized for preparing c-skAuD. DOX was successfully loaded, as confirmed by the FT-IR results. In addition, FT-IR characterization revealed that chondroitin sulfate and collagen in the extract were involved in the synthesis of skAu. Although c-skAuD is cytotoxic to four different types of cancer cells (AGS, HeLa, A549 and MDA-MB-231), their cytotoxic effects were greatest on MDA-MB-231 cells. Analyzing cytotoxicity onto MDA-MB-231 cells revealed that c-skAuD had the greatest cytotoxicity, followed by a positive control (c-citAuD) and DOX. Furthermore, this cytotoxicity was dependent on the incubation time and DOX concentration. Cellular uptake of Au by inductively coupled plasma‒mass spectrometry demonstrated that compared with AGS cells (15.1%), MDA-MB-231 cells showed approximately two-fold greater Au uptake (29.9%) of c-skAuD. However, the Au uptake of the positive control (c-citAuD) did not significantly differ between the MDA-MB-231 and AGS cells. Moreover, collagen type II was identified in the extract by peptide analysis using LC‒ESI‒MS/MS. To the best of our knowledge, we are the first to report collagen type II in D. chilensis cartilage.

Indexed as

Collagen type IIDipturus chilensis cartilageDoxorubicinGold nanoparticlesMDA-MB-231 cellsPeptide analysisUpcycling strategy

Identifiers

PMID40246748
PMCPMC12006596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.